Tango Therapeutics Valuation
| TNGX Stock | USD 12.51 0.56 4.69% |
At this time, the company appears to be overvalued. Tango Therapeutics has a current Real Value of $11.93 per share. The regular price of the company is $12.51. Our model measures the value of Tango Therapeutics from inspecting the company fundamentals such as Return On Equity of -0.52, shares outstanding of 134.68 M, and Operating Margin of 0.26 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Tango Therapeutics' valuation include:
Price Book 10.3765 | Enterprise Value | Enterprise Value Ebitda (0.91) | Price Sales 24.201 | Enterprise Value Revenue 23.1954 |
Overvalued
Today
Please note that Tango Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Tango Therapeutics is based on 3 months time horizon. Increasing Tango Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Tango Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tango Stock. However, Tango Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.51 | Real 11.93 | Target 14.38 | Hype 12.56 | Naive 11.48 |
The intrinsic value of Tango Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tango Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tango Therapeutics helps investors to forecast how Tango stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tango Therapeutics more accurately as focusing exclusively on Tango Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Tango Therapeutics' intrinsic value based on its ongoing forecasts of Tango Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Tango Therapeutics' closest peers.
Tango Therapeutics Cash |
|
Tango Therapeutics Total Value Analysis
Tango Therapeutics is at this time forecasted to have valuation of 1.54 B with market capitalization of 1.61 B, debt of 36.49 M, and cash on hands of 416.36 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tango Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.54 B | 1.61 B | 36.49 M | 416.36 M |
Tango Therapeutics Investor Information
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.91. Tango Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Tango Therapeutics' liquidity, profitability, solvency, and operating efficiency, Tango Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Tango Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Tango Therapeutics has an asset utilization ratio of 13.29 percent. This suggests that the Company is making $0.13 for each dollar of assets. An increasing asset utilization means that Tango Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Tango Therapeutics Profitability Analysis
Based on Tango Therapeutics' profitability indicators, Tango Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Tango Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -38.9 M | Current Value 15.9 M | Quarterly Volatility 13.2 M |
For Tango Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tango Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tango Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tango Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tango Therapeutics over time as well as its relative position and ranking within its peers.
Tango Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Tango Therapeutics is estimated to be -0.323575 with future projections ranging from a low of -0.38 to a high of -0.2825. Tango Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.91. Please be aware that the consensus of earnings estimates for Tango Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Tango Therapeutics Earnings Estimation Breakdown
The calculation of Tango Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Tango Therapeutics is estimated to be -0.323575 with the future projection ranging from a low of -0.38 to a high of -0.2825. Please be aware that this consensus of annual earnings estimates for Tango Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.38 Lowest | Expected EPS | -0.28 Highest |
Tango Therapeutics Earnings Projection Consensus
Suppose the current estimates of Tango Therapeutics' value are higher than the current market price of the Tango Therapeutics stock. In this case, investors may conclude that Tango Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Tango Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 10 | 75.23% | 0.0 | -0.323575 | -0.91 |
Tango Therapeutics Ownership Allocation
Tango Therapeutics shows a total of 134.68 Million outstanding shares. The majority of Tango Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tango Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tango Therapeutics. Please pay attention to any change in the institutional holdings of Tango Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that roughly five million eight hundred fourty-four thousand nine hundred eighty-six invesors are currently shorting Tango Therapeutics expressing very little confidence in its future performance.Tango Therapeutics Profitability Analysis
The company reported the previous year's revenue of 42.07 M. Net Loss for the year was (130.3 M) with loss before overhead, payroll, taxes, and interest of (67.5 M).About Tango Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Tango Therapeutics. We calculate exposure to Tango Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tango Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 48.4 M | 25.5 M | |
| Pretax Profit Margin | (3.56) | (3.73) | |
| Operating Profit Margin | (3.98) | (4.18) | |
| Net Loss | (3.56) | (3.74) | |
| Gross Profit Margin | 0.71 | 0.74 |
Tango Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Tango Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Tango we look at many different elements of the entity such as Tango's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Tango Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Tango Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Tango Therapeutics' worth.Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.